Sector News

DSM in talks to acquire postbiotics producer Adare Biome

April 22, 2023
Life sciences

DSM has entered into negotiations with Adare Pharma Solutions to acquire Adare Biome, a developer and manufacturer of postbiotics, for an enterprise value of €275 million.

Adare Biome’s origins date back to 1907 when French chemist Pierre Boucard launched Lactéol, a supplement for relieving gut troubles. Available over the counter in 35 countries, Lactéol is said to be “one of the most scientifically well-documented microorganism-based therapeutics in the world in terms of efficacy and safety”.

DSM hopes to expand the availability of the supplement through its business-to-consumer unit, i-Health. In addition, the ingredients giant plans to further develop Adare Biome’s postbiotic business-to-business ingredient, while leveraging its potential in dietary supplements, early life and medical nutrition, and nutritional improvement for the under-nourished.

Tom Sellig, CEO of Adare Pharma Solutions, commented: “DSM would be the ideal company to take Adare Biome to a new level and realise the growth potential of postbiotics. They have the infrastructure and strong commercialisation and science capabilities to scale the significant scientific research achieved over the years, and DSM’s mission to create healthier lives for all will resonate strongly with the team.”

Philip Eykerman, DSM’s executive vice president health, nutrition & care, said: “Adare Biome would be a perfect fit for DSM, with pioneering science that will complement each of our three businesses. The Adare Biome team will greatly help in accelerating our ‘health from the gut’ strategy as there is considerable untapped potential for next-generation biotics to support the health of people and animals.”

The transaction remains subject to consultation with the workers council and customary regulatory conditions.

By Gwen Jones

Source: foodbev.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach